NasdaqCM:SNSS

Stock Analysis Report

Executive Summary

Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of solid and hematologic cancers.


Snowflake Analysis

Excellent balance sheet with limited growth.

Share Price & News

How has Sunesis Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: SNSS's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-11.1%

SNSS

4.2%

US Biotechs

5.3%

US Market


1 Year Return

-73.7%

SNSS

1.6%

US Biotechs

-10.7%

US Market

Return vs Industry: SNSS underperformed the US Biotechs industry which returned 1.6% over the past year.

Return vs Market: SNSS underperformed the US Market which returned -10.7% over the past year.


Shareholder returns

SNSSIndustryMarket
7 Day-11.1%4.2%5.3%
30 Day-64.0%-3.9%-13.6%
90 Day17.6%-5.2%-19.8%
1 Year-73.7%-73.7%2.4%1.6%-8.9%-10.7%
3 Year-90.1%-90.1%14.2%11.3%15.5%8.0%
5 Year-97.4%-97.4%-4.1%-8.4%35.2%20.4%

Price Volatility Vs. Market

How volatile is Sunesis Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Sunesis Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

2.82x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate SNSS's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate SNSS's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: SNSS is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: SNSS is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SNSS's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SNSS is overvalued based on its PB Ratio (2.8x) compared to the US Biotechs industry average (2.6x).


Next Steps

Future Growth

How is Sunesis Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

-7.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SNSS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SNSS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SNSS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: SNSS's revenue (62.3% per year) is forecast to grow faster than the US market (7.2% per year).

High Growth Revenue: SNSS's revenue (62.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if SNSS's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Sunesis Pharmaceuticals performed over the past 5 years?

9.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: SNSS is currently unprofitable.

Growing Profit Margin: SNSS is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: SNSS is unprofitable, but has reduced losses over the past 5 years at a rate of 9.1% per year.

Accelerating Growth: Unable to compare SNSS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SNSS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (22%).


Return on Equity

High ROE: SNSS has a negative Return on Equity (-84.7%), as it is currently unprofitable.


Next Steps

Financial Health

How is Sunesis Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: SNSS's short term assets ($36.3M) exceed its short term liabilities ($9.4M).

Long Term Liabilities: SNSS's short term assets ($36.3M) exceed its long term liabilities ($281.0K).


Debt to Equity History and Analysis

Debt Level: SNSS's debt to equity ratio (19.8%) is considered satisfactory.

Reducing Debt: SNSS's debt to equity ratio has reduced from 66.8% to 19.8% over the past 5 years.


Balance Sheet

Inventory Level: SNSS has a low level of unsold assets or inventory.

Debt Coverage by Assets: SNSS's debt is covered by short term assets (assets are 6.6x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SNSS has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: SNSS has less than a year of cash runway if free cash flow continues to grow at historical rates of 9.6% each year.


Next Steps

Dividend

What is Sunesis Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate SNSS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate SNSS's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SNSS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SNSS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SNSS's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.2yrs

Average management tenure


CEO

Dayton Misfeldt (45yo)

2.17s

Tenure

US$574,939

Compensation

Mr. Dayton Misfeldt has been an Interim CEO of Sunesis Pharmaceuticals, Inc. since January 1, 2018 and as its Director since April 2009. Mr. Misfeldt serves as Managing Director and Investment Partner at B ...


Leadership Team

NamePositionTenureCompensationOwnership
Dayton Misfeldt
Interim CEO & Director2.17yrsUS$574.94kno data
William Quinn
Senior VP of Finance & Corporate Development and CFO2.33yrsUS$501.17k0.10% $48.0k
Judith Fox
Chief Scientific Officer and Executive VP of Research & Development3.17yrsno data0.036% $16.7k
Stephen Nava
Vice President of Quality Assurance1.67yrsno datano data
Deborah Thomas
Senior Vice President4.08yrsno datano data
Parvinder Hyare
Senior Vice President of Commercial0.67yrno datano data
Sean Gharpurey
Executive Director of Project Management1.67yrsno datano data
Daniel Swisher
Strategic Advisor2.17yrsUS$565.45kno data

2.2yrs

Average Tenure

48yo

Average Age

Experienced Management: SNSS's management team is considered experienced (2.2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Dayton Misfeldt
Interim CEO & Director2.17yrsUS$574.94kno data
David Stump
Independent Director13.75yrsUS$92.74kno data
Nicole Onetto
Director0.50yrno datano data
James Young
Non-Executive Chairman16.25yrsUS$105.24k0.0062% $2.8k
Henry Wolff
Independent Director2.08yrsUS$276.08kno data
Steven Ketchum
Independent Director8.08yrsUS$87.74k0.010% $4.6k
Homer Pearce
Independent Director13.75yrsUS$99.62kno data
Stefano Carchedi
Independent Director6.75yrsUS$110.24kno data

9.5yrs

Average Tenure

66yo

Average Age

Experienced Board: SNSS's board of directors are considered experienced (9.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 144.9%.


Top Shareholders

Company Information

Sunesis Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Sunesis Pharmaceuticals, Inc.
  • Ticker: SNSS
  • Exchange: NasdaqCM
  • Founded: 1998
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$46.217m
  • Shares outstanding: 111.39m
  • Website: https://www.sunesis.com

Number of Employees


Location

  • Sunesis Pharmaceuticals, Inc.
  • 395 Oyster Point Boulevard
  • Suite 400
  • South San Francisco
  • California
  • 94080
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
A2ARHWDB (Deutsche Boerse AG)COM PAR USD0.0001 (POST REV SPLT)DEEURNo data
SNSSNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDSep 2005
RYIPDB (Deutsche Boerse AG)YesCommon StockDEEURSep 2005
RYIPBRSE (Berne Stock Exchange)YesCommon StockCHCHFSep 2005

Biography

Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of solid and hematologic cancers. Its lead program is vecabrutinib, a non-covalent inhibitor of Bruton’s tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial in B-cell malignancies. The company is also developing SNS-510, which is in preclinical pharmacology studies for the treatment of solid tumor and hematologic malignancies; TAK-580, a pan-Raf inhibitor program that is in Phase 1 clinical trial for the treatment of pediatric low-grade glioma; and vosaroxin, a topoisomerase 2 inhibitor, which completed a Phase 3 trial in patients with relapsed or refractory acute myeloid leukemia. It has a collaboration agreement with Biogen Idec MA, Inc. to discover, develop, and commercialize small molecule BTK inhibitors; and license agreement with Takeda Pharmaceutical Company Limited to develop and commercialize preclinical inhibitors of PDK1. Sunesis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in South San Francisco, California. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/01 00:13
End of Day Share Price2020/03/31 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.